肿瘤防治研究
腫瘤防治研究
종류방치연구
CANCER RESEARCH ON PREVENTION AND TREATMENT
2001年
3期
188-190
,共3页
p16%多功能抗体%免疫组织化学
p16%多功能抗體%免疫組織化學
p16%다공능항체%면역조직화학
目的制备抗p16INK-4多克隆抗体,并探计p16蛋白的表达与胃癌预后的关系。方法以人工合成p16INK-4N-末端13个氨基酸多肽与匙孔虫戚血蓝蛋白(KLH)交联物为抗原,制备抗p16多克隆抗体(PoAbs)。使用此多抗,采用S—P免疫组织化学方法,检测30例胃癌组织中p16蛋白的表达。结果30例胃癌组织中,9例p16表达阴性随访8年死亡率100%、中位生存期8个月;21例表达阳性死亡率57.1%、中位生存期33个月,二者生存期存在显著性差异(P<0.01)。结论(1)使用自制PoAbs可替代进口多抗体在临床、科研中的应用;(2)提示p16蛋白的表达与胃癌预后关系密切。
目的製備抗p16INK-4多剋隆抗體,併探計p16蛋白的錶達與胃癌預後的關繫。方法以人工閤成p16INK-4N-末耑13箇氨基痠多肽與匙孔蟲慼血藍蛋白(KLH)交聯物為抗原,製備抗p16多剋隆抗體(PoAbs)。使用此多抗,採用S—P免疫組織化學方法,檢測30例胃癌組織中p16蛋白的錶達。結果30例胃癌組織中,9例p16錶達陰性隨訪8年死亡率100%、中位生存期8箇月;21例錶達暘性死亡率57.1%、中位生存期33箇月,二者生存期存在顯著性差異(P<0.01)。結論(1)使用自製PoAbs可替代進口多抗體在臨床、科研中的應用;(2)提示p16蛋白的錶達與胃癌預後關繫密切。
목적제비항p16INK-4다극륭항체,병탐계p16단백적표체여위암예후적관계。방법이인공합성p16INK-4N-말단13개안기산다태여시공충척혈람단백(KLH)교련물위항원,제비항p16다극륭항체(PoAbs)。사용차다항,채용S—P면역조직화학방법,검측30례위암조직중p16단백적표체。결과30례위암조직중,9례p16표체음성수방8년사망솔100%、중위생존기8개월;21례표체양성사망솔57.1%、중위생존기33개월,이자생존기존재현저성차이(P<0.01)。결론(1)사용자제PoAbs가체대진구다항체재림상、과연중적응용;(2)제시p16단백적표체여위암예후관계밀절。
Objective To prepara Polyclonal antibodies(PoAbs) of p16INK-4 andinvestigate the relationship between expression of p16 and prognosis of gastric cancer.Methods (1)PoAbs against peptide containing 13 amino acids of the N-end of human p16 was obtained in rabbits by immunization with the peptide conjugated with KLH. (2)The expression of p16 protein in 30 gastric cancer was studied immunohistochemically.Results In 30 cases gastric cancer with 8-years follow-up period, 9 cases of p16 expression negative were died(9/9), The medium survival time was 8 months; 12 cases of p16 expression positive were died(12/12), with medum survival time for 33 months. Patients with negative p16 expression survived for a significantly shorter period of time than those with positive p16 expression (P<0.01).Conclusion (1)PoAbs to p16 obtained in this study are fully comparable to that ones purchased abroad both in specificity and in sensitivity for IHC assay of the paraffin embedded tissue.(2)expression of p16 gene is closely related to the prognsis of gastric cancer.